Key Points
- Director Philip Wagenheim sold a total of 65,000 Immunome shares in two transactions (36,800 on Mar 20 at $20.47 and 28,200 on Mar 23 at $20.65), generating about $1.34M and reducing his stake to 341,147 shares.
- Immunome is a clinical-stage biotech trading near $20.75 with a market cap of $2.35B; it recently missed quarterly EPS (‑$0.75 vs. ‑$0.65), shows very negative margins/ROE, but analysts hold a consensus "Moderate Buy" and a target price of about $33.45 (individual targets up to $40).
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Philip Wagenheim sold 28,200 shares of the firm's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $20.65, for a total value of $582,330.00. Following the completion of the transaction, the director owned 341,147 shares of the company's stock, valued at approximately $7,044,685.55. This represents a 7.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Philip Wagenheim also recently made the following trade(s):
- On Friday, March 20th, Philip Wagenheim sold 36,800 shares of Immunome stock. The shares were sold at an average price of $20.47, for a total value of $753,296.00.
Immunome Trading Up 3.7%
Shares of Immunome stock opened at $20.75 on Tuesday. The company's 50-day moving average price is $22.76 and its 200-day moving average price is $18.64. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $27.65. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -8.57 and a beta of 2.12.
Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. On average, sell-side analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current year.
Institutional Trading of Immunome
Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company's stock valued at $316,000 after buying an additional 14,398 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Immunome by 6.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company's stock valued at $17,305,000 after acquiring an additional 117,523 shares during the last quarter. Creative Planning purchased a new stake in Immunome during the 2nd quarter valued at about $167,000. Intech Investment Management LLC boosted its holdings in Immunome by 17.8% during the 2nd quarter. Intech Investment Management LLC now owns 40,565 shares of the company's stock valued at $377,000 after acquiring an additional 6,141 shares during the period. Finally, Swiss National Bank grew its position in Immunome by 3.8% during the 2nd quarter. Swiss National Bank now owns 132,800 shares of the company's stock worth $1,235,000 after acquiring an additional 4,800 shares during the last quarter. 44.58% of the stock is owned by institutional investors.
Analyst Ratings Changes
IMNM has been the topic of several research analyst reports. Evercore upped their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an "outperform" rating in a report on Tuesday, December 16th. Wall Street Zen cut Immunome from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Lake Street Capital upped their target price on Immunome from $22.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, December 16th. Leerink Partners set a $40.00 price target on Immunome in a report on Monday, December 15th. Finally, Craig Hallum lifted their price target on Immunome from $33.00 to $36.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $33.45.
Check Out Our Latest Analysis on Immunome
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
